Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, announced today the appointment of Dr. Steven Rosenberg, Chief of the Surgery Branch at the National Cancer Institute, to their Scientific and Medical Advisory Board. Dr. Rosenberg pioneered the development of immunotherapy as a successful treatment for select patients with advanced cancer.
Genesis Biopharma is currently working on the development and commercialization of treatments for various cancers, including a product known as Contego, which is a ready-to-infuse autologous cell therapy that uses tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Genesis Biopharma has licensed rights from the National Institutes of Health to certain intellectual property relating to the use of adoptive cell therapy for the treatment of metastatic melanoma, ovarian, breast and colorectal cancers.
“We are honored to have Dr. Rosenberg serve on our Scientific and Medical Advisory Board. A leading authority on immunology and cancer, Dr. Rosenberg pioneered adoptive cell therapy using autologous tumor infiltrating lymphocytes (TILs) to successfully treat patients with metastatic melanoma,” stated Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma in a press release.
“As the inventor of this therapy, Dr. Rosenberg will be an invaluable asset to Genesis Biopharma as we advance the clinical development for Contego™, our ready-to-infuse adoptive cell therapy using TILs, to treat Stage IV metastatic melanoma.”
Dr Rosenberg works as a Professor of Surgery in Washington DC at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences. Dr. Rosenberg is the author of more than 820 articles on various aspects of cancer research in the scientific literature, has authored eight books and is a named inventor on 189 patent and patent applications. A 1999 study published by the Institute for Scientific Information showed that Dr. Rosenberg was the most-cited clinician in the world in the field of oncology for the 17 years between 1981 and 1998.
For more information, please visit www.genesis-biopharma.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment